Respiratory syncytial virus (RSV) is a common cause of respiratory illness in infants and young children, as well as older adults. Each season, RSV causes substantial morbidity and mortality in older adults, including lower respiratory tract disease, hospitalisation, and death.  

Arexvy is a vaccine that causes the immune system to produce RSV antibodies. It includes an adjuvant which is a component that enhances the immune response to the vaccination.  Arexvy became available in New Zealand in May 2024. It is not yet funded on the immunisation schedule, but is available for purchase. 

It is currently approved for use in adults 60 years and older to protect against symptomatic lower respiratory tract disease caused by RSV. 

A single dose of Arexvy is highly effective at preventing serious respiratory illness from RSV for at least two seasons, or 18 months (around 80% effective). Trials continue to establish further duration for protection, and it is unclear whether booster doses will be required. 

Further information can be reviewed via the following links: 

• Immunisation Advisory Committee - Arexvy 
• Healthify - Arexvy 

Please email our nursing team at nurse@mtedenvillagedoctors.co.nz if you wish to purchase an Arexvy vaccination.